Alliance Pharma plc

APH

GB0031030819

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:09 2024-04-26 am EDT			5-day change	1st Jan Change
34.95 ^GBX	+0.14%		-5.16%	-13.70%

Apr. 22	EARNINGS: Lok'n Store has "positive but muted" growth as Shurgard bids	AN
Apr. 22	Alliance Pharma plc Announces Delay in Publication of Preliminary Earnings Results for the Year Ended December 31, 2023	CI

Alliance Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023

September 26, 2023 at 02:00 am EDT

Alliance Pharma plc reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was GBP 81.4 million compared to GBP 78.77 million a year ago. Net income was GBP 5.11 million compared to GBP 13.1 million a year ago.

Basic earnings per share from continuing operations was GBP 0.0095 compared to GBP 0.0243 a year ago. Diluted earnings per share from continuing operations was GBP 0.0094 compared to GBP 0.024 a year ago.

Latest news about Alliance Pharma plc

EARNINGS: Lok'n Store has "positive but muted" growth as Shurgard bids	Apr. 22	AN
Alliance Pharma plc Announces Delay in Publication of Preliminary Earnings Results for the Year Ended December 31, 2023	Apr. 22	CI
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05	AN
Alliance Pharma Chair to Step Down; Successor Named	Feb. 05	MT
Alliance Pharma plc Announces Board Changes	Feb. 05	CI
Jefferies raises Spirax-Sarco; cuts Victrex	Jan. 31	AN
Alliance Pharma reports annual boost in revenue; eyes flat 2024 profit	Jan. 29	AN
Alliance Pharma plc Announces Appointment of Non-Executive Directors	Nov. 07	CI
Barclays ups Rio Tinto; Liberum likes Indivior	23-10-24	AN
Barclays cuts United Utilities and Severn Trent	23-09-28	AN
Alliance Pharma first half profit plunges, stops dividend payout	23-09-26	AN
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 Revenue GBP81.4M	23-09-26	MT
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 EPS GBX0.94	23-09-26	MT
Alliance Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023	23-09-26	CI
High demand, low supplies for Novo's weight-loss drug launch in Germany	23-08-24	RE
Exane raises Segro; Goldman likes Aston Martin	23-07-19	AN
FTSE Closes Tuesday Up 0.6% Lifted by Banks, Oil Stocks; Ocado Soars	23-07-18	DJ
UK Consumers Cut Spending Amid Rising Mortgage Rates	23-07-18	DJ
Alliance Pharma interim see-through revenue climbs	23-07-18	AN
Alliance Pharma votes approved despite sizeable opposition	23-05-25	AN
FTSE 100 Closes Down 0.7% Dragged by Oil Stocks, US Debt-Ceiling Standoff	23-05-25	DJ
BOE Rate Rise of More Than 25Bps Looks Unlikely	23-05-25	DJ
Alliance Pharma annual profit "marginally below" forecasts	23-05-25	AN
Alliance Pharma Four-Month Sales Rose on Year, But Sees Full-Year FX Hit	23-05-25	DJ

Chart Alliance Pharma plc

Duration

Period

More charts

Company Profile

Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alliance Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3495 GBP

Average target price

0.6743 GBP

Spread / Average Target

+92.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ALLIANCE PHARMA PLC	-13.70%	235M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals